Seeking Alpha

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual ...

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and ...
Seeking Alpha

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a ...
MarketWatch

Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

The MarketWatch News Department was not involved in the creation of this content. Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell ...
GEN

Alnylam, Regeneron Launch $1B RNAi Collaboration Focused on Eye, CNS, Liver Disorders

Alnylam Pharmaceuticals will partner with Regeneron Pharmaceuticals to discover, develop, and commercialize RNA interference (RNAi) therapeutics for diseases of the eye and CNS—as well as advance ...